Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cardiff Oncology Inc. (CRDF)

Cardiff Oncology Inc. (CRDF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 113,618
  • Shares Outstanding, K 19,968
  • Annual Sales, $ 240 K
  • Annual Income, $ -16,410 K
  • 60-Month Beta 1.48
  • Price/Sales 477.60
  • Price/Cash Flow N/A
  • Price/Book 10.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.79
  • Growth Rate Est. (year over year) +126,555.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.10 +49.02%
on 07/20/20
6.85 -10.79%
on 08/05/20
+1.25 (+25.72%)
since 07/07/20
3-Month
0.82 +640.61%
on 05/08/20
6.85 -10.79%
on 08/05/20
+4.92 (+413.45%)
since 05/07/20
52-Week
0.70 +771.61%
on 03/19/20
6.85 -10.79%
on 08/05/20
+4.41 (+259.41%)
since 08/07/19

Most Recent Stories

More News
Cardiff Oncology to Participate in Fireside Chat at the Virtual BTIG Biotechnology Conference

, /PRNewswire/ --(Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal...

CRDF : 6.11 (+7.38%)
Cardiff Oncology to Participate in the William Blair Biotech Focus Conference

, /PRNewswire/ --(Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal...

CRDF : 6.11 (+7.38%)
Advancements in Breast Cancer Research & Clinical Studies Producing Optimism for New Treatments

, /PRNewswire/ -- The triple negative breast cancer (TNBC) treatment market to grow at stellar CAGR through 2026. A  from Cole Market Research has stated that the ongoing advancements in cancer research...

ONCY : 1.8900 (-5.03%)
ONC.TO : 2.56 (-0.39%)
GNPX : 3.56 (-0.84%)
CRDF : 6.11 (+7.38%)
MRK : 81.02 (-0.04%)
LLY : 152.93 (+0.03%)
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital

, /PRNewswire/ -- (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal...

CRDF : 6.11 (+7.38%)
Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML

, /PRNewswire/ -- , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer,...

CRDF : 6.11 (+7.38%)
Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation

, /PRNewswire/ --(Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal...

CRDF : 6.11 (+7.38%)
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO

, /PRNewswire/ -- , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer,...

CRDF : 6.11 (+7.38%)
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer

, /PRNewswire/ --(Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal...

CRDF : 6.11 (+7.38%)
Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures

, /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including...

CRDF : 6.11 (+7.38%)
Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer

, /PRNewswire/ --  (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal...

CRDF : 6.11 (+7.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CRDF with:

Business Summary

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of...

See More

Key Turning Points

2nd Resistance Point 6.59
1st Resistance Point 6.35
Last Price 6.11
1st Support Level 5.66
2nd Support Level 5.21

See More

52-Week High 6.85
Last Price 6.11
Fibonacci 61.8% 4.50
Fibonacci 50% 3.78
Fibonacci 38.2% 3.05
52-Week Low 0.70

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar